Chief economist of CITIC Jiantou: More active finance and moderately loose currency are beneficial to both stocks and debts. Huang Wentao, chief economist of CITIC Jiantou, interpreted the Central Economic Work Conference and said that the meeting stressed that it is necessary to maintain stable economic growth next year, maintain overall stability in employment and prices, raise the fiscal and monetary adjustment to the strongest level for many years, and give priority to expanding domestic demand. The construction of modern industrial system focuses on new quality productivity, and the economic system reform has landmark measures to expand autonomy and unilateral opening up in an orderly manner to stabilize the property market and stock market. Stable employment and stable prices will bring about both nominal and real growth, more active finance and moderately loose currency, which will be beneficial to both stocks and debts, the stock index, valuation and liquidity will stabilize and rebound, and the bond market interest rate will have more downside. Looking forward to 2025, the 5% real and nominal GDP growth rate is the direction of efforts. The growth is more brought about by the domestic demand boost and two innovations, new quality productivity and new supply, industrial digitalization and digital industrialization, rural revitalization and new urbanization, Belt and Road Initiative and opening up, and the high-quality ending of the "14 th Five-Year Plan" started the "15 th Five-Year Plan".Chongda Technology: Five measures are taken to deal with the challenges and opportunities of industry development. Chongda Technology (002815) said in the online collective reception day of investors on December 12 that the company's measures to deal with the challenges and opportunities of industry development include: optimizing product structure, continuing to promote the optimization and upgrading of product structure, increasing R&D investment and market expansion in the field of high-end PCB boards, and accelerating the introduction of high-value customers and orders; Improve production efficiency and cost control; Accelerate the pace of capacity expansion, and promote the speed of capacity improvement of Dalian Plant, Zhuhai No.1 Plant and Zhuhai No.2 Plant in an orderly manner; According to market demand, adjust product price strategy in real time to improve profitability; Accelerate the construction of production base in Thailand, actively participate in international competition and cooperation, and enhance the company's visibility and influence in the global PCB market.Most gold stocks in Hong Kong stocks fell, and Lingbao Gold fell by nearly 5%. As of press time, Lingbao Gold (03330.HK) fell by 4.75%, Zijin Mining (02899.HK) fell by 2.82% and Zhaojin Mining (01818.HK) fell by 2.75%.
Microsoft: The latest small language model PHI-4, which is specially used for complex reasoning, is introduced.Xray, an important partner of Yizhizhuang, officially announced a strategic cooperation with Google. According to Yizhizhuang, at the Android XR conference held in new york, Google officially announced a strategic cooperation with Xray to jointly build the Android XR ecosystem. This cooperation not only highlights XREAL's position as the world's largest manufacturer of AR glasses, but also marks a new stage of accelerated popularization of XR industry. It is noteworthy that Lingyizhi, as a long-term strategic partner of XREAL, provides key components and assembly services for XREAL AR glasses.Klarna, a Swedish payment company, said that it stopped recruiting hundreds of employees because of AI during the year. Sebastian Siemiatkowski, CEO of Klarna, a Swedish payment company planning to go public in the US, said that the company stopped recruiting a year ago, mainly because it invested in artificial intelligence (AI), which can replace the work of hundreds of employees in the company. According to Siemiatkowski, the number of employees decreased by 22% to 3,500 within one year, mainly due to brain drain. He pointed out that at present, about 200 employees in the company use artificial intelligence for their core work, and will improve the efficiency of artificial intelligence by accelerating the salary growth of employees.
Yin Xiyue continued to exercise the presidential power to submit the consent of the appointment of the chief justice to the National Assembly. According to the information system of the Korean National Assembly's motion, South Korean President Yin Xiyue submitted the consent of the appointment of the chief justice to the National Assembly on the 12 th, and said that "with the end of the term of office of the chief justice, in order to appoint a successor judge, the consent of the National Assembly is requested." Yin Xiyue delivered a speech to the people on the 12th, refused to end his term of office ahead of schedule, and successively approved 42 bills and enforcement orders, and also submitted a consent case for the appointment of the chief justice to continue to exercise the presidential power. According to the Korean Constitution, the Chief Justice shall be submitted by the President of the Grand Court of Korea (the High Court) and appointed by the President with the consent of the National Assembly. (CCTV News)Treasury bond futures opened, with 30-year main contracts rising by 0.48%, 10-year main contracts rising by 0.36%, 5-year main contracts rising by 0.25% and 2-year main contracts rising by 0.05%.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)